Journal article
Calcitonin gene-related peptide (CGRP): a new target for migraine
Annual review of pharmacology and toxicology, Vol.55(1), pp.533-552
2015
DOI: 10.1146/annurev-pharmtox-010814-124701
PMCID: PMC4392770
PMID: 25340934
Abstract
Migraine is a neurological disorder that manifests as a debilitating headache associated with altered sensory perception. The neuropeptide calcitonin gene-related peptide (CGRP) is now firmly established as a key player in migraine. Clinical trials carried out during the past decade have proved that CGRP receptor antagonists are effective for treating migraine, and antibodies to the receptor and CGRP are currently under investigation. Despite this progress in the clinical arena, the mechanisms by which CGRP triggers migraine remain uncertain. This review discusses mechanisms whereby CGRP enhances sensitivity to sensory input at multiple levels in both the periphery and central nervous system. Future studies on epistatic and epigenetic regulators of CGRP actions are expected to shed further light on CGRP actions in migraine. In conclusion, targeting CGRP represents an approachable therapeutic strategy for migraine.
Details
- Title: Subtitle
- Calcitonin gene-related peptide (CGRP): a new target for migraine
- Creators
- Andrew F Russo - Departments of 1Molecular Physiology and Biophysics and
- Resource Type
- Journal article
- Publication Details
- Annual review of pharmacology and toxicology, Vol.55(1), pp.533-552
- DOI
- 10.1146/annurev-pharmtox-010814-124701
- PMID
- 25340934
- PMCID
- PMC4392770
- NLM abbreviation
- Annu Rev Pharmacol Toxicol
- ISSN
- 0362-1642
- eISSN
- 1545-4304
- Publisher
- United States
- Grant note
- NS075599 / NINDS NIH HHS R01 NS075599 / NINDS NIH HHS
- Language
- English
- Date published
- 2015
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984020796802771
Metrics
21 Record Views